Rx PHARMASIST.CA
The Pharmasist newsletter

Stay current in
Canadian pharmacy.

Pharmacy news, practice updates and fresh perspectives—delivered to your inbox.

Keep your practice informed

  • Canadian pharmacy news

    Follow the developments shaping the profession.

  • Prescriber updates

    Stay informed about newly licensed Ontario physicians.

  • What's new on Pharmasist

    Explore new resources, tools and learning opportunities.

Free newsletter

A useful addition to your inbox.

We'll send a confirmation link first. Privacy policy

Hormone replacement therapy (estrogen/progestogen combination)

Estradiol / Progesterone

Bijuva

Dosage form
Tablet
Available strengths
0.5 mg estradiol/100 mg progesterone, 1 mg estradiol/100 mg progesterone
Drug class
Hormone replacement therapy (estrogen/progestogen combination)
Common brand
Bijuva

Clinical overview. Bijuva is a combined hormone replacement therapy capsule containing estradiol and micronized progesterone, used to treat moderate to severe hot flashes and night sweats associated with menopause in women with an intact uterus. It is taken once daily in the evening with food, at the lowest effective dose for the shortest duration needed, and carries increased risks of blood clots, stroke, and breast cancer with longer-term use.

Indication

Common therapeutic uses

  • Bijuva is used to treat moderate to severe hot flashes and night sweats (vasomotor symptoms) associated with menopause.
  • Bijuva is intended only for women with an intact uterus, since the progesterone component helps protect the uterine lining from the effects of unopposed estrogen.

Pregnancy

Risk assessment and monitoring considerations

Contraindicated in pregnancy. Confirm pregnancy status and discuss alternative therapy with the prescriber before dispensing.

  • Bijuva must not be used during pregnancy or if pregnancy is suspected.
  • If pregnancy occurs while taking Bijuva, the medication should be stopped immediately.

Breastfeeding

Infant exposure considerations

  • Bijuva must not be used while breastfeeding.

Geriatrics

Dosing and tolerability considerations

  • Bijuva has not been studied in women over 65 years of age and is not recommended for use in this age group.
  • Combined estrogen-progestin therapy in women 65 and older may increase the risk of developing dementia.

Pediatrics

Use in children and adolescents

  • Bijuva is not indicated for use in children or adolescents.

Dosage & Administration

Practical dosing and administration

  • The recommended dose of Bijuva is one capsule taken by mouth every evening with food.
  • Bijuva should be used at the lowest effective dose and for the shortest duration consistent with treatment goals, with periodic reassessment of whether continued treatment is needed.
  • If a dose is missed, it should be taken as soon as possible unless it is almost time for the next dose, in which case the missed dose should be skipped; doses should never be doubled.
  • Missing a dose may increase the chance of breakthrough bleeding or spotting.

Overdose

Recognizing and responding to overdose

If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.

  • Overdose with the estrogen component may cause nausea, breast discomfort, fluid retention, bloating, or vaginal bleeding.
  • Overdose with the progesterone component may cause low mood, tiredness, acne, or excess hair growth (hirsutism).
  • Large accidental ingestions in children have not been reported to cause serious acute harm.
  • Management of overdose is supportive and symptomatic, with close observation of the patient.

Common side effects

Frequently reported tolerability concerns

  • Headache may occur.
  • Nasal and throat infection (nasopharyngitis) may occur.
  • Breast tenderness may occur.
  • Upper respiratory tract infection may occur.
  • Nausea may occur.
  • Back pain may occur.
  • Abdominal pain or bloating may occur.
  • Sinus infection (sinusitis) may occur.
  • Dizziness may occur.
  • Vaginal bleeding or spotting may occur.
  • Vaginal discharge may occur.
  • Pelvic pain or uterine cramping may occur.
  • Weight gain may occur.
  • Hair loss (alopecia) or acne may occur.

Serious side effects

Findings that may require urgent assessment

Serious side effects require immediate discussion with the prescriber or emergency care.

  • Bijuva may increase the risk of blood clots, including deep vein thrombosis and pulmonary embolism.
  • Bijuva may increase the risk of stroke and heart attack.
  • Bijuva may increase the risk of invasive breast cancer with longer-term use.
  • Bijuva may increase the risk of endometrial hyperplasia or endometrial cancer if the progesterone component is not taken consistently as directed.
  • Bijuva may increase the risk of probable dementia in women 65 years of age and older.
  • Gallbladder disease requiring surgery may occur.
  • Severe allergic reactions, including hypersensitivity, have been reported.
  • Acute pancreatitis has been reported, particularly in women with elevated triglycerides.
  • Liver problems, including abnormal liver function tests and jaundice, may occur.
  • Vision changes, including retinal blood vessel blockage, may occur.
  • Seek urgent medical attention for chest pain, sudden shortness of breath, leg swelling or pain, sudden severe headache, vision loss, weakness on one side of the body, or signs of a serious allergic reaction.

Use with caution

Situations requiring closer assessment

  • Use with caution in women with a personal or strong family history of breast cancer.
  • Use with caution in women with high triglyceride levels, since Bijuva can raise triglycerides further and increase the risk of pancreatitis.
  • Use with caution in women with diabetes or risk factors for diabetes, as glucose tolerance may worsen.
  • Use with caution in women with liver or gallbladder disease.
  • Use with caution in women with uterine fibroids or endometriosis, which can worsen with estrogen therapy.
  • Use with caution in women with a history of high blood pressure, since blood pressure should be monitored during treatment.
  • Use with caution in women with epilepsy, migraine, porphyria, systemic lupus erythematosus, or otosclerosis, all of which may be aggravated by estrogen therapy.
  • Use with caution in women scheduled for surgery; Bijuva should be stopped at least 4 weeks beforehand if possible due to clot risk.

Contraindications

Situations where therapy may be inappropriate

  • Contraindicated in patients with known hypersensitivity to Bijuva or any ingredient in the formulation.
  • Contraindicated in patients with liver disease or abnormal liver function tests that have not returned to normal.
  • Contraindicated in patients with known, suspected, or a personal history of breast cancer or other estrogen- or progestogen-sensitive cancer.
  • Contraindicated in patients with endometrial hyperplasia.
  • Contraindicated in patients with undiagnosed abnormal vaginal bleeding.
  • Contraindicated during known or suspected pregnancy.
  • Contraindicated while breastfeeding.
  • Contraindicated in patients with a current or past history of arterial blood clots, such as stroke or heart attack.
  • Contraindicated in patients with classical migraine.
  • Contraindicated in patients with a current or past history of venous blood clots, such as deep vein thrombosis or pulmonary embolism.
  • Contraindicated in patients with partial or complete vision loss due to eye blood vessel disease.

Drug interactions

Clinically relevant combinations

  • Drugs that induce liver enzymes, such as barbiturates, phenytoin, carbamazepine, meprobamate, phenylbutazone, or rifampicin, can reduce the effectiveness of Bijuva.
  • St. John's Wort and other CYP3A4-inducing herbal or anticonvulsant products can lower hormone levels and reduce effectiveness.
  • Strong or moderate CYP3A4 inhibitors, such as azole antifungals, macrolide antibiotics, verapamil, and diltiazem, can raise hormone levels and increase the risk of side effects.
  • Certain anti-HIV and anti-hepatitis C protease inhibitors and non-nucleoside reverse transcriptase inhibitors can raise or lower hormone levels, affecting safety and effectiveness.
  • Bijuva may reduce the effectiveness of anticoagulants, oral antidiabetic medications, and antihypertensive medications.
  • Acute alcohol intake can raise circulating estradiol levels.

Food interactions

Meal-related administration

  • Bijuva must be taken with food; a meal increases and stabilizes absorption of the estradiol component.
  • Grapefruit juice can inhibit drug-metabolizing enzymes and raise estrogen levels, increasing the risk of side effects, so it should be used cautiously.

Time of administration

Practical scheduling

  • Bijuva is taken once daily in the evening, with food, at approximately the same time each day.

Storage

Product handling

  • Store Bijuva at room temperature, between 15°C and 25°C, protected from light.

Patient take-away

Key counselling points for a quick closing summary

  • Bijuva combines estrogen and progesterone to relieve moderate to severe menopausal hot flashes and night sweats in women who still have their uterus.
  • Take Bijuva exactly as prescribed, at the lowest effective dose for the shortest time needed, with periodic reassessment by a healthcare provider.
  • Report any unexpected vaginal bleeding, breast changes, leg swelling, chest pain, sudden headache, or vision changes promptly.
  • Keep up with recommended breast exams, mammograms, and any other monitoring your healthcare provider suggests.

References

Source material and product information

  1. Health Canada Product Monograph — Estradiol / Progesterone

For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.